Vox Markets Logo

Venture Life enters 5-year agreement for Gelclair with Jaguar Health, renews financing

11:20, 19th April 2024
Paul Hill
PMH Capital

Hot on the heels of last week's positive FY'23 results, consumer healthcare products firm Venture Life Group (VLGFollow | VLG said today that it had signed a new exclusive 5 year deal for Gelclair (an FDA-approved oral mucositis prescription gel) with Jaguar Health in the US. The agreement covers future license fees, royalties and product revenues to VLG.

CEO Jerry Randall adding: "This new agreement will ensure the continued supply of Gelclair to US oncology patients suffering oral mucositis, and generate meaningful additional revenues."

But that's not all. VLG has also successfully renegotiated its RCF banking agreement with Santander and HSBC.

The new 3 year funding package (incl a 12 month option to extend) provides £30m of borrowing at an interest rate of 2.0%-2.85% above SONIA/EURIBOR. The facility is limited to 2.5x EBITDA for the previous 12 month period - including the trailing EBITDA from any acquisitions. On top, VLG has access to another £20m - subject to certain conditions but on the same terms as the RCF.

Any cash drawn down can be used for acquisitions, working capital or any other business activity.

CFO Daniel Wells commenting: "Santander and HSBC have been supportive partners to Venture Life Group over the past 3 years, and we are delighted to complete our refinancing with them. The teams from across both lenders have been excellent to work with, and understand our business and the Consumer Healthcare sector well."

Hence allowing the group to further accelerate its expansion strategy - combining both organic and acquisitive growth. Cavendish have a price target of 68p/share.

Stock Chart | VLG

Follow News & Updates from Venture Life Group: Follow | VLG


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles